Home › Funds › Affinity Asset Advisors, LLC › FBRX
Affinity Asset Advisors, LLC position in FBRX
FORTE BIOSCIENCES INC
Affinity Asset Advisors, LLC reported holding 1,145,391 shares of FBRX (FORTE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$24.3M, representing 1.17% of its reported portfolio and ranking #26 among its reported holdings. Affinity Asset Advisors, LLC has disclosed FBRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's FBRX position evolved
Affinity Asset Advisors, LLC first disclosed a stake in FBRX in Q4 2025 at 22,400 shares (US$611K). The position peaked in Q1 2026 at 1,011,890 shares, worth US$26.2M. Across 3 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,145,391 shares valued at US$24.3M — an increase of 133,501 shares quarter over quarter.. Notable position changes include a 4417% increase in Q1 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 22.40K | $610.85K | New |
| Q1 2026 | 1.01M | $26.21M | Add |
| Q2 2026 | 1.15M | $24.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FBRX and 13F data
FBRX (FORTE BIOSCIENCES INC) is a company whose sector is not yet classified in our data. 70 other funds we track also report a position in FBRX — the largest reported positions include ORBIMED ADVISORS LLC (US$33.5M), MPM BioImpact LLC (US$21.0M), TCG Crossover Management, LLC (US$19.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FBRX
- ORBIMED ADVISORS LLC 1.58M sh · $33.53M · Q2 2026
- MPM BioImpact LLC 987.45K sh · $20.98M · Q2 2026
- TCG Crossover Management, LLC 920.00K sh · $19.55M · Q2 2026
- Integral Health Asset Management, LLC 675.00K sh · $14.34M · Q2 2026
- Cable Car Capital, LP 400.00K sh · $8.50M · Q2 2026
- Boxer Capital Management, LLC 274.50K sh · $5.83M · Q2 2026
- Trails Edge Capital Partners, LP 273.18K sh · $5.81M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 249.69K sh · $5.31M · Q2 2026
- Squadron Capital Management LLC 225.00K sh · $4.78M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held FBRX?
Affinity Asset Advisors, LLC has disclosed FBRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Affinity Asset Advisors, LLC's current position in FBRX?
As of Q2 2026, Affinity Asset Advisors, LLC holds 1.15M shares of FBRX (FORTE BIOSCIENCES INC), valued at $24.34M, representing 1.17% of its reported portfolio and ranking #26.
Has Affinity Asset Advisors, LLC been buying or selling FBRX?
In the latest 13F filing (Q2 2026), Affinity Asset Advisors, LLC increased its position in FBRX. The position peaked in Q1 2026 at 1.01M shares.
Which other funds hold FBRX?
Other major institutional holders of FBRX include ORBIMED ADVISORS LLC, MPM BioImpact LLC, TCG Crossover Management, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.